clinical trial · NCT07312903
DPTX3186 in Wnt Pathway Activated Solid Tumors
Solid TumorsDPTX3186
brief summary
This is a first-in human clinical study of DPTX3186 in subjects with Wnt-pathway activated solid tumors where no other treatments exist. The study will evaluate safety, pharmacokinetics, and initial activity of DPTX3186, as well as explore pharmacodynamic parameters to identify potential biomarkers of efficacy
started
Jan 1, 2026
primary completion
May 31, 2028
completion
Jun 30, 2028
last updated
Jan 12, 2026
official title
An Open Label, Multicenter Study of DPTX3186 to Evaluate Safety, Tolerability, and Pharmacokinetics in Subjects With Known Wnt Pathway Activated Solid Tumors Where No Other Treatments Exist
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol